Regulation of human renal adenocarcinoma cell growth by retinoic acid and its interactions with epidermal growth factor  by Argilés, Àngel et al.
Kidney International, Vol. 45 (1994), PP. 23—31
Regulation of human renal adenocarcinoma cell growth by
retinoic acid and its interactions with epidermal growth factor
ANGEL ARGILES,' TETSUYA OOTAKA, PRUDENCE A. HILL, DAVID J. NIKOLIC-PATERSON,
PAUL HUTCHINSON, NORBERT E. KRAFT, and ROBERT C. ATKINS
Department of Nephrology, Monash Medical Centre, Clayton, and Department of Anatomy, University of Melbourne, Parkville,
Victoria, Australia
Regulation of human renal adenocarcinoma cell growth by retinoic acid
and its interactions with epidermal growth factor. Retinoic acid (RA) is
a natural derivative of vitamin A which regulates the growth and
differentiation of epithelia. We have previously proposed that RA
participates in compensatory kidney growth and reported that RA
inhibits rat mesangial cell growth. This paper describes the effects of
RA on a human renal adenocarcinoma cell line (PAD) under different
growth conditions, and its interactions with epidermal growth factor
(EGF). PAD cells were shown to express RA receptors a and /3 by
Northern blot analysis. In serum free cultures, addition of RA (10—v M)
markedly increased thymidine incorporation by PAD cells (155 7%
mean SE vs. control in 6 separate experiments; P < 0.0001). RA also
caused a significant increase in thymidine incorporation by PAD cells
under conditions of rapid growth in serum supplemented medium (115
2% vs. control; P < 0.001). RA by itself was unable to reverse
contact inhibition of PAD cell growth (NS vs. control), but it synergis-
tically enhanced the mitogenic effect of EGF on confluent monolayers
(110 0.6% vs. EGF alone; P < 0.05). Northern blot analysis
demonstrated that PAD cells express EGF receptor mRNA, and this
was not significantly modified by the addition of RA. Growth arrested
(serum starved) PAD cells expressed RAR-a mRNA which was up-
regulated eightfold at three hours following the addition of 10% FCS.
Thus, our data show that RA is directly mitogenic for serum starved
human renal adenocarcinoma cells and that it exerts complex modula-
tion of cell growth in the presence of EGF and serum components.
Cell replication and proliferation constitutes a complex pro-
cess which is seen in normal and in pathological states. Rem-
nant kidney hypertrophy following uninephrectomy is one of
the few physiological occasions during which an organ grows in
adulthood. Although it is known that in compensatory kidney
growth increase in cell size is more important than cell division,
the factors modulating this process are not completely under-
stood [1].
Among the mechanisms of induction of kidney hypertrophy,
the participation of renotropic factors has been widely studied
[2]. However, no specific renal growth factor has been success-
fully characterized as the major determinant for compensatory
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kidney growth. The renal effects of polypeptide growth factors
have been reviewed [3]. One of them, epidermal growth factor
(EGF) has been related to compensatory kidney growth [4].
Glomerular mesangial cells respond to EGF [5] and receptors
for this peptide have been identified in the basolateral side of
tubular cells [6, 7]. The kidney is able to produce EGF and the
main site of renal EGF production has been identified as the
ascending limb of Henle [8, 9].
Proteins are, however, not the only factors involved in
compensatory kidney growth. Previous studies with human
kidney donors established a role for retinoids in the post-
nephrectomy adaptation process [10]. A local modification of
the cytosolic receptor for retinoic acid (CRABP, cellular reti-
noic acid binding protein) was observed as well as systemic
modifications of retinol and retinol binding protein [10]. Since
retinoids are essential for growth and maintenance of epithelia
[11, 121, we postulated that retinoic acid (RA) may participate in
human kidney hypertrophy [10]. However, apart from fibro-
blasts, few data are available describing the effects of RA on
kidney cells. Recently, two reports have analyzed the effects of
RA on animal-derived renal epithelial cell lines. The canine
MDCK cells responded to RA addition with increased dome
formation [13], and we observed changes in cell cycle and
protein content of the rabbit RK13 cell line [14]. We have now
extended these observations to a human renal adenocarcinoma
cell line, including a study of the role of RA and its interactions
with EGF in cell growth.
Methods
Cell culture
PAD cells were obtained from an axillary lymph node metas-
tasis of an adenocarcinoma of renal origin. Although of tumoral
origin, PAD cells conserve contact inhibition properties [15].
PAD cells were used between passages 20 and 40. For mainte-
nance, cells were cultured in plastic flasks with RPMI 1640
medium supplemented with 10% fetal calf serum (FCS)
(GIBCO, Grand Island, New York, USA) and maintained at
37°C in 5% CO2. PAD cell assays were performed in 96 well
trays (Disposable Products). After trypsinization 5000 cells/well
were randomly plated in 10% FCS supplemented RPMI 1640
and used for assay both before (day 1) and after confluent
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monolayers were obtained (day 4). PAD cells were also ana-
lyzed at days 1 and 4 in serum free medium in order to assess
the effect of the retinoic acid and EGF in growth factor free
medium as described by VanZoelen, vanOostwaard and de
Laat [16].
Electron microscopy
PAD cell cultures were rinsed twice in 0.1 M phosphate
buffered saline pH 7.4 and detached from plastic flasks with a
cell scraper. The cell pellet was fixed in 2.5% glutaraldehyde
and post-fixed in 2% osmium tetroxide. An albumin block of the
cells was prepared by adding one drop of 20% FCS to one drop
of 5% glutaraldehyde followed by centrifugation. The pellet was
then fixed in 2.5% glutaraldehyde, processed through graded
acetones and embedded in epon Araldite. Thin sections were
examined in the electron microscope.
Immunohistochetnistry
PAD cells were cultured on glass slides, fixed in 4%
paraformaldehyde for 10 minutes, and permeabilized in 0.2%
Triton X-100 for two minutes. The fixed cells were then
incubated with specific primary antibodies followed by a bio-
tinylated second antibody and horseradish peroxidase-conju-
gated streptavidin. Bound peroxidase enzyme was visualized
using the diaminobenzidine substrate. Monoclonal antibodies
used were: CAM 5.2, anticytokeratins 8, 18, 19 (Becton Dick-
inson, New Jersey, USA); 34 pE12, anticytokeratins 1, 5, 10,
14 (Dako, Copenhagen, Denmark); and anti-epithelial mem-
brane antigen (EMA) (Dako). Rabbit polyclonal antibodies used
were: anticarcinoembryonic antigen (CEA); antivimentin; and
antiCD2O (pan B cells) (all from Dako).
Growth factors
RA, EGF and retinol (vitamin A) were purchased from Sigma
Chemical Co. (St. Louis, Missouri, USA). RA (1O- M), EGF (4
ng/ml) and retinol (106 M) were added 24 hours before harvest-
ing for thymidine incorporation assay. Other concentrations
were used as specified.
DNA synthesis
DNA was monitored by thymidine incorporation as previ-
ously described [17]. A 16 hour pulse of 0.5 CiJwell 3H
radiolabeled thymidine (27 Cilmmol; Amersham International,
Amersham, UK) was used. One rinse (200 pA) with warm PBS
and two rinses with 5% trichloroacetic acid were performed
after removing the medium. Two successive 50 pA aliquots of
0.2 NaOH were added and left at 37°C for 10 minutes, then
added to scintillation vials containing 100 pA of 0.2 N HCI and
3.5 ml of scintillation fluid. The counts per minute were
determined with a LKB WALLACE 1214 (LKB, Upsala,
Sweden) beta counter. Twelve replicates were performed in
each experiment.
Cell cycle analysis
Cell cycle analysis of PAD cells was performed by flow
cytometry as previously described [14] using propidium iodide
dye [18]. Briefly, a single cell suspension in 2 ml PBS with 10%
FCS was treated with 0.5 ml of propidium iodide (250 sg/ml in
1% NP-40) for 10 minutes in the dark on ice in the presence of
25 g of RNase. Cells were passed through a 50 sm mesh to
remove cell aggregates, and the fluorescence measured within
two minutes on an EPICS 752 (Coulter Electronics, Miami,
Florida, USA) flow cytometer. The EPICS argon laser was
tuned to a wavelength of 488 nm, at a power of 600 mW, for
excitation of the propidium iodide dye. Size measurements of
the cells was based on light scatter collected in the forward
angle (FALS) direction. DNA fluorescence emissions were
measured through a 630 nm long pass filter. Fluorescence
versus FALS scattergrams and single color histograms of the
DNA staining pattern were analyzed. Cell cycle analysis based
on DNA content distribution was performed using the PARA 1
software package. This program assumes Gaussian distribu-
tions for both the Go/Gi and G2+M cells and calculates the
percentage of cells in these peaks. The percentage of cells in S
phase is then measured by subtracting the other phases from the
total.
RNA preparations and Northern blot hybridization
PAD cells grown in 175 cm2 plastic flasks were harvested
following trypsinization and RNA prepared by acid guanidin-
ium thiocyanate-phenol-chioroform extraction [19]. Northern
blotting of RNA samples used standard methods of denatur-
ation with glyoxal and dimethylsulphoxide, size fractionation
on 1.2% agarose gels and capillary blotting onto Hybond-N
membranes (Amersham) [20]. Membranes were hybridized at
42°C overnight with 32P-labeled cDNA probes in 5 x SSPE/50%
formamide/0.2 mg/ml herring sperm DNAJO.2 mg/mi yeast
RNAJO.5% SDS/5x Denhardt's. Membranes were washed in
2x SSC/0.1% SDS at room temperature and in 0.2x SSC/0.1%
SDS at 50°C for 30 minutes each. Hybridization with the 18S
RNA oligonucleotide used the same buffer at 50°C overnight,
followed by washing at room temperature as above and then in
0.1 x SSC/0. 1% SDS at 55°C. Autoradiographs were exposed
for three to seven days with intensifying screens at —70°C.
Densitometry measurements of autoradiographs used the Cue 2
Image Analyzer program (Olympus).
Probe preparation
eDNA probes used were as follows: human RAR-a was a 0.6
kb restriction fragment from the hT1R clone [21]; human
RAR-p was a 1.4 kb cDNA clone containing the entire coding
region [22]; human EGF-R probe was a Xbal/Kpnl 2.7 kb
eDNA fragment [23]. Probes were labeled with [a-32P]-dCTP
(Amersham International) to a specific activity of >iO
cpm/mg DNA using a random priming kit (Boehringer, Mann-
heim, Germany). An 18 s rRNA 30 mer oligonucleotide probe
(5' GACACCATI'AAGATCTCGArFATGTACGGC 3') [24]
was end labeled with ['y-32P]-dATP (Amersham International)
using a T4 polynucleotide kinase (Boehringer).
Statistical analysis
The Student's t-test was used to analyze differences between
groups in each experiment. Student's t-test for paired data was
used when several experiments were tested at the same time.
Fisher's F analysis of the variance was used to assess differ-
ences between two groups with several data points. The results
are expressed as mean standard error of the mean (sEM) and
a P value lower than 0.05 is taken as significant.
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Fig. 1. Transmission electron micrographs of cultured PAD cells. (a) The cell surface shows short microvilli (arrowheads) and there is complex
infolding of the cell membrane (*). The nucleus is irregular with two prominent nucleoli. An intercellular junction is present between the two cells
(arrow) (x6100). (b) The intercellular junction is characterized by poorly differentiated desmosomes (arrows) (X30,000). (C) Further sections of the
same intercellular junction reveal the presence of a poorly formed tight junction (arrow) (x30,000).
Results
Characterization of PAD cells
The epithelial nature of PAD cells was examined by electron
microscopy and immunohistochemistry. On electron micros-
copy, PAD cells demonstrated marked pleomorphism, abun-
dant often vacuolated cytoplasm, irregular surface microvihi
and intracytoplasmic lumina. Occasional intercellular junctions
were seen which were characterized by poorly differentiated
desmosomes and poorly formed tight junctions (Fig. 1). PAD
cells had an epithelial morphology under light microscopy and
displayed an immunohistochemical phenotype consistent with
their origin from a renal adenocarcinoma: strong staining with
antivimentin (3+); moderate staining with CAM 5.2 anticyto-
keratin 8, 18, 19 antibody (2+); weak positive staining with
anti-S 100 (1+) (Fig. 2). This immunohistochemical phenotype
was identical in both dispersed and confluent cell layers. No
staining of PAD cells was apparent with antibodies to cytoker-
atins 1, 5, 10, 14(34/3E12), EMA, CEA or CD2O. Further
characterization of PAD cells has been reported elsewhere [15].
Effects of RA and EGF in serum free medium
To determine the effects of RA and avoid interferences with
other serum components we used growth factor free cultures as
described by VanZoelen et al [16]. These cultures were main-
tained for four days without FCS, followed by the addition of
either RA and/or EGF. RA alone significantly increased thymi-
dine incorporation (155 7% of the control; P < 0.0001) as did
EGF (177 10%; P < 0.0001; Fig. 3). The addition of both
growth factors together had an additive effect (208 25%; P <
0.0001; Fig. 3).
As an alternative means of assessing cell division, cell cycle
analysis was used. Following exposure to l0 M RA, there was
an increase in the number of cycling cells (G2+M phase cells)
(Fig. 4). In three separate experiments, the mean increase of
cells in G2+M phases was 18 4% (P <0.001 vs. control).
Effects of RA, EGF and retinol in serum supplemented
medium
To assess whether RA could augment PAD cell proliferation
under conditions of rapid cell growth, nonconfluent cultures
supplemented with 10% FCS were examined. Addition of RA
increased the rate of thymidine incorporation in rapidly growing
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Fig. 2. Antibody staining of cultured PAD cells by the immunoperoxidase method. (a) Vimentin (3+), (b) cytokeratins 8, 18, 19(2+), (c) S100 (1+),
and (d) CD2O negative.
cells (Fig. 5a). To verify that increased thymidine incorporation
was associated with an increase in cell proliferation, daily cell
counts of PAD cultures in the presence and absence of RA were
performed. The results in Figure 6 show a significant increase in
cell number of rapidly growing cells in the presence of iO M
RA. The ability of RA to reverse contact inhibition was
investigated. Addition of RA to PAD cells grown to confluence
in FCS supplemented medium made no difference to thymidine
uptake (101 2% of control; NS). However, in these same
cultures RA (10—v M) enhanced the EGF stimulation of conflu-
ent cells, even though it had no direct effect by itself (Fig. 5b, c,
d).
The effect of retinol on PAD cell growth was also assessed.
Retinol (106, 10, and i0 M) was added to rapidly growing
cells in serum supplemented medium and caused no significant
change in thymidine incorporation (94%, 95% and 93% of
control, respectively). A similar result was observed in conflu-
ent PAD cultures in the presence of serum: 10 M retinol did
not modify thymidine incorporation (8902 426 vs. control
8933 447 cpm; NS).
Dose dependency of growth factor responses
The stimulation obtained with RA in serum deprived cultures
(Fig. 7) and in rapidly growing cells (Fig. 8) was dose depen-
dent. The magnitude of the RA effect on FCS stimulated cells
was smaller as could be expected from cells already in rapid
growth. In both cases, maximal stimulation was obtained at
lO M. Increasing the dose to 10_6 M resulted in a marginally
lower response.
The stimulatory effect of EGF in confluent cultures was also
dose dependent; optimum responses were obtained at 0.3 to 3
0
C8
nglml. Addition of RA (10—v M) increased the level of the EGF
response by more than 30%, but did not change the half-





Fig. 3. Effect of RA and EGF on serum-free cultures. PAD cell
proliferation was assessed by 3H-thymidine incorporation. Each bar
represents the percent variation from control values from 6 separate
experiments, with 12 replicates in each experiment. Additive responses
were observed in cultures containing both RA and EGF. (*P <0.001 vs.
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Fig. 5. Effects of RA and its interactions with EGF in FCS supple-
mented cultures. PAD cell proliferation was assessed by 3H-thymidine
uptake. Cells were maintained with 10% FCS supplemented RPMI
1640. Each bar represents the percent of the control values from 6
separate experiments, with 12 replicates in each experiment. (a) RA(l0 M) effect on rapidly growing cultures, (b) RA (l0 M) effect on
contact inhibited cultures, (c) EGF (4 ng/ml) effect on contact inhibited
cultures, and (d) EGF + RA effect on contact inhibited cultures.
0.05 vs. control, #P < 0.05 EUF vs. EGF + RA.
may indicate that RA does not alter the affinity of EGF for its
receptor.
Expression of growth factor receptor mRNA species
PAD cells were analyzed for the expression of mRNA
encoding receptors for EGF (EGF-R) and RA (RAR-a), Con-
Fig. 4. Cell cycle analysis in serum-free
cultures. Flow cytometric analysis showing
that incubation of PAD cells with l0 M RA
increased the number of cells entering into the
cell cycle (S and G2+M phases).
Time, days of counting
Fig. 6. Effect of RA on daily cell counting of PAD cell cultures in rapid
growth. Four thousand cells/well were cultured in 96 well plates and
counted daily after trypsinization. The results are expressed as percent-
age of the count on day 0, which is taken as control. Six wells contained
lO M RA (•) and 6 wells FCS alone (L). RA induced a significant
increase in cell numbers on days 2, 3 and 4 (P < 0.05) (analysis of the
variance of the two curves. F 7.97; P < 0.048).
fluent PAD cells expressed both a major high molecular weight
(approximately 10 kb) and a minor lower molecular weight
(approximately 6 kb) mRNA species of the EGF-R (Fig. lOa).
Confluent PAD cells expressed two mRNA species for
RAR-a (Fig. lob). The size of the RAR-a mRNA bands was
consistent with that found in studies of other cell types [21, 25].
In addition, confluent PAD cells expressed two niRNA species
for the RAR-/3 (not shown). As a control, the human K562
erythroleukemic cell line was examined and shown to express
to RAR-a (but not RAR-j3 mRNA) as previously described [25].
The effect of growth factor treatment on the expression of
these receptor mRNA species was investigated. Confluent PAD
A RA-
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Fig. 8. Dose-response study of RA effect on 10% FCS supplemented
non-confluent PAD cultures. PAD cell proliferation was assessed by
3H-thymidine uptake. Cells were cultured with RPM! 1640 supple-
mented with 10% FCS, and the effect of varying concentrations of RA
determined.
cells were incubated for three or six hours with iO—, l0, l0
M RA and for 24 hours with io— M RA. In addition, confluent
PAD cells were incubated for three or six hours with 1 ng/ml of
EGF. There was no consistent change in the level of expression
of EGF-R, RAR-a, or RAR-/3 mRNA. Results from 24 hour
incubation with l0 M RA treatment are shown in Figure 10.
The expression of RAR-a mRNA was investigated under
different growth conditions. PAD cells in growth arrest ex-
pressed RAR-a mRNA, although this was eightfold lower than
the level of expression in confluent cells (Fig. ii). The addition
of FCS to growth arrested cells resulted in an eightfold up-
regulation of RAR-a mRNA which was down-regulated by 24
hours (Fig. 11).
Discussion
Retinoids have been classically studied in dermatology and
oncology [26], and the range of metabolic activities known to be
induced by retinoids is very broad. RA has been shown to
modify superoxide production in HL6O cells [27]; increase
receptor numbers for vasoactive intestinal peptide in neuroblas-
toma cells [28]; up-regulate macrophage phagocytosis and lym-
phocyte response to interleukin-1 [29]; inhibit proliferation of
monocyte-derived U937 cells [301; or redifferentiate HL6O cell
line, slowing down the cell cycle [31] and preventing c-myc
overexpression [32]. RA and EGF are systemic growth factors
[26, 33] that are locally synthesized in the kidney [8, 9, 34, 35]
and the kidney expresses receptors for both of them [6, 7, 25,
361. They are known to interact in several different metabolic
systems [37—39], and both RA [10] and EGF [4] have been
implicated in compensatory kidney growth. However, while
EGF has been widely studied, fewer reports exist that assess
RA effects on renal cells [13, 14, 40].
In the present study, the response of a human renal adeno-
carcinoma cell line to RA was determined. The malignant origin
of PAD cells was confirmed by ultrastrutural morphological
examination. Evidence of secretory behavior and intracytoplas-
mic lumina and the identification of intercellular junctions
strongly support the origin of the cells from an adenocarcinoma.
The co-expression of low molecular weight cytokeratins [8, 18,







Fig. 7. Dose-response study of RA effect on serum-free PAD cultures.
PAD cell proliferation was assessed by 3H-thymidine uptake. Cells
were maintained for 4 days in RPM! 1640 medium without FCS
supplementation and then varying concentrations of RA added.






Fig. 9. Dose-response curve of EGF effect in the absence (I) or
presence of i0 M RA (0), PAD cell proliferation was assessed by
3H-thymidine uptake. Cells were grown to confluence in RPMI 1640
supplemented with 10% FCS and the effect of EGF and EGF + RA
additions assessed.
T
ctrl 10 100 101
II I .2 .1 .4 .1
A EGF-R B RARx
renal cell carcinoma [41, 42]. In addition, Sl00 antigen expres-
sion by PAD cells is also consistent with a renal cell carcinoma
[43].
It was demonstrated that RA alone was able to induce growth
of serum starved PAD cells. Interestingly, RA was also able to
further enhance DNA synthesis in already rapidly growing PAD
cells and this mitogenic effect was observed at physiological
concentrations (normal RA serum level is 3 to 4 nglml, or 108
M). However, no mitogenic response was observed when RA
was added to confluent cultures. This finding contrasted with
our previous observations in a rabbit renal epithelial cell line
(RK13), where RA induced similar changes in thymidine incor-
poration in both confluent and rapidly growing cells [14].
It is known that RA can freely diffuse into the cell cytoplasm
without the need for a specific carrier or membrane receptor
[44]. The sequence and organ distribution for CRABP has been
reported [36, 45] and four RA receptors with a nuclear binding
portion (RAR alpha, beta, gamma and epsilon) have been
identified [21, 22, 46, 47]. The RAR-p beta gene has a RA
responsive element [48] which triggers RA up-regulation of
RAR-p gene transcription [48]. However, RA has also been
found to modify erythrocyte metabolism, therefore proving that
not all RA actions require nuclear involvement [49].
While several tissues (including the kidney) have been found
to express RA receptors and different cell lines have also been
tested [21, 25, 47, 50], no published data are available regarding
their expression on kidney cell lines or isolates. In the present
study, we demonstrated that renal adenocarcinoma cells ex-
Fig. 10. EGF-R and RAR-a gene expression
by PAD cells. Total cellular RNA was
prepared from confluent PAD cells maintained
for 24 hours with or without iO M RA, and
from K562 cell line (control). RNA (15 zg/
lane) was analyzed by Northern blotting using
the following cDNA probes: (A) EGF-R, and
(B) RAR-a. The position of the 18s and 28s
rRNA is shown.
press both RAR-a and RAR-f3 mRNA. Further, we found
RAR-a and RAR-/3 mRNA expression in confluent cultures,
while in this situation RA did not elicit any change in thymidine
incorporation. However, other factors related to contact inhi-
bition may account for the lack of RA mitogenic activity. We
cannot exclude though that RA induces metabolic changes
other than thymidine incorporation, which may also be relevant
for cellular growth [27, 39, 49, 51]. RAR-a mRNA was also
expressed in starved PAD cells, and this expression was
significantly increased at three and six hours following addition
of FCS. These results suggest that RAR expression and RA
activity are determined to some degree by the growth status of
the cell.
EGF was mitogenic in confluent monolayers of PAD and this
effect was also dose related. We observed that RA enhanced
EGF mitogenic activity on confluent monolayers of PAD cells
in serum supplemented medium. RA increased the maximal
EGF response by an additional 30%. Mordan reported appar-
ently contradictory results, observing that RA and retinyl
acetate inhibited PDGF- and EGF-induced growth in rat fibro-
blasts [52]. Another report on rat mesangial cells showed that
EGF can block RA-induced collagen synthesis [53]. Alterna-
tively, RA has been found to increase EGF binding to its
receptor in a fetal rat lung cell line [39] and in mouse mammary
gland cells [54]. In mouse palatal mesenchymal cells, low
concentrations of RA (10 M) enhanced EGF induced mitoge-
nicity without modifying EGF receptor mRNA expression [55].
In our study RA enhanced EGF mitogenic effect on PAD cells
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Fig. 11. Effect of growth conditions upon PAD cell RAR-a gene
expression. Total cellular RNA was prepared from PAD cells under the
following conditions: (a) growth arrested, (b) 3 hours and (C) 24 hours
following the addition of 10% FCS to growth arrested cells, and (d) cells
grown to confluence in 10% FCS. RNA (15 pg/lane) was analyzed by
Northern blotting using probes for: RAR-a (upper panel) and 18S rRNA
(lower panel). The position of the 18S and 28S rRNA is shown on the
upper panel. The ratio of RAR-a mRNAJ18s rRNA is shown, normal-
ized to 1.0 for lane (a).
at iO M without markedly increasing EGF receptor mRNA
expression. Although post-translational changes are not ruled
out by our experiments, it seems feasible that RA triggers other
cellular modifications to increase EGF responsiveness in PAD
rather than causing major increase in EGF receptor expression.
These findings indicate several potential modes of action by
which RA could up-regulate kidney cell growth. The direct
effect of RA in serum starved cultures suggests that it can act as
a mitogen in its own right. The augmentation of fetal calf
serum-mediated growth in rapidly growing cultures also argues
that RA induces positive signals in the presence of other
cytokines. In the context of compensatory kidney growth,
however, it is likely that the confluent cultures most closely
resemble the cell densities and proportion of dividing cells to be
found in the intact organ. It is therefore of interest that in these
conditions RA also acted synergistically with EGF. Given the
putative role of the latter cytokine in compensatory kidney
growth [4] we would suggest that RA may be similarly involved,
particularly as increased cellular retinoic acid binding protein
(CRABP) levels have been described in the remnant kidney
[10].
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